Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.32
-0.06 (-2.52%)
(As of 11/1/2024 ET)

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.32
$2.39
50-Day Range
$2.29
$2.51
52-Week Range
$1.67
$3.67
Volume
31,029 shs
Average Volume
132,152 shs
Market Capitalization
$94.58 million
P/E Ratio
4.55
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
36th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 36% of companies evaluated by MarketBeat, and ranked 767th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from $0.24 to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is 4.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.86.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is 4.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 128.50.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Oramed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.73% of the outstanding shares of Oramed Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 12.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.73% of the outstanding shares of Oramed Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 12.31%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    8 people have searched for ORMP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORMP Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Oramed Pharm (ORMP) Receives a Hold from H.C. Wainwright
3 Micro-Cap Moonshots for Fearless Investors
Oramed Letter to Shareholders
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.31 on January 1st, 2024. Since then, ORMP shares have increased by 0.4% and is now trading at $2.32.
View the best growth stocks for 2024 here
.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) posted its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.01 by $0.21.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
8/14/2024
Today
11/01/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
Employees
10
Year Founded
N/A

Profitability

Net Income
$5.53 million
Pretax Margin
1,518.25%

Debt

Sales & Book Value

Annual Sales
$1.34 million
Book Value
$4.04 per share

Miscellaneous

Free Float
35,184,000
Market Cap
$94.58 million
Optionable
Optionable
Beta
1.77

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners